TBI is a major cause of death and disability in the United States; DRG Epidemiology estimates that there were 250,000 moderate to severe TBI events diagnosed in U.S. hospitals / emergency rooms in 2019. Although numerous generic drugs are available to manage acute-phase risks and chronic symptoms / deficits (e.g., pain, psychiatric problems, motor problems), no therapies are FDA approved to treat any aspect of TBI. As such, the opportunity for proven symptomatic or, more importantly, neuroprotective / restorative compounds for use in the acute and rehabilitation settings is entirely untapped. The TBI pipeline is small and evolving, but development challenges abound, and repeated failures in treating this complex disorder have stunted progress. A solid grasp of the addressable TBI market, the current state of management, and the future competitive landscape will lay the foundation for new players entering this space.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.